Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-12

AUTHORS

Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly

ABSTRACT

BACKGROUND: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease. HER2-based vaccines induce polyclonal antibody responses against HER2 that demonstrate enhanced anti-tumor activity when combined with lapatinib in murine models. We wished to test the clinical safety, immunogenicity, and activity of a HER2-based cancer vaccine, when combined with lapatinib. METHODS: We immunized women (n = 12) with metastatic, trastuzumab-refractory, HER2-overexpressing breast cancer with dHER2, a recombinant protein consisting of extracellular domain (ECD) and a portion of the intracellular domain (ICD) of HER2 combined with the adjuvant AS15, containing MPL, QS21, CpG and liposome. Lapatinib (1250 mg/day) was administered concurrently. Peripheral blood antibody and T cell responses were measured. RESULTS: This regimen was well tolerated, with no cardiotoxicity. Anti-HER2-specific antibody was induced in all patients whereas HER2-specific T cells were detected in one patient. Preliminary analyses of patient serum demonstrated downstream signaling inhibition in HER2 expressing tumor cells. The median time to progression was 55 days, with the majority of patients progressing prior to induction of peak anti-HER2 immune responses; however, 300-day overall survival was 92% (95% CI: 77-100%). CONCLUSIONS: dHER2 combined with lapatinib was safe and immunogenic with promising long term survival in those with HER2-overexpressing breast cancers refractory to trastuzumab. Further studies to define the anticancer activity of the antibodies induced by HER2 vaccines along with lapatinib are underway. TRIAL REGISTRY: ClinicalTrials.gov NCT00952692. More... »

PAGES

28

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1479-5876-10-28

DOI

http://dx.doi.org/10.1186/1479-5876-10-28

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045174623

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22325452


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibody Formation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Demography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epitopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Structure, Tertiary", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-akt", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vaccination", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamilton", 
        "givenName": "Erika", 
        "id": "sg:person.01315576133.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315576133.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blackwell", 
        "givenName": "Kimberly", 
        "id": "sg:person.01264356120.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264356120.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hobeika", 
        "givenName": "Amy C", 
        "id": "sg:person.07741424047.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07741424047.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GlaxoSmithKline Biologicals, Rixensart, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clay", 
        "givenName": "Timothy M", 
        "id": "sg:person.0706420433.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706420433.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Cancer Statistical Center, Duke Cancer Institute, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Broadwater", 
        "givenName": "Gloria", 
        "id": "sg:person.0610532363.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610532363.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ren", 
        "givenName": "Xiu-Rong", 
        "id": "sg:person.01032053762.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032053762.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Wei", 
        "id": "sg:person.014466504320.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014466504320.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GlaxoSmithKline Biologicals, Rixensart, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castro", 
        "givenName": "Henry", 
        "id": "sg:person.01137075433.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137075433.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GlaxoSmithKline Biologicals, Rixensart, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lehmann", 
        "givenName": "Frederic", 
        "id": "sg:person.01245021610.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245021610.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spector", 
        "givenName": "Neil", 
        "id": "sg:person.01242656120.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242656120.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wei", 
        "givenName": "Junping", 
        "id": "sg:person.01037147437.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037147437.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osada", 
        "givenName": "Takuya", 
        "id": "sg:person.01114717615.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114717615.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lyerly", 
        "givenName": "H Kim", 
        "id": "sg:person.012507420117.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012507420117.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-2549", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000633777"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.21.4437", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001671107"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-010-9415-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006267870", 
          "https://doi.org/10.1007/s10637-010-9415-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2007-02-075945", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006579746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-2484", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009361534"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn759", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011354734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.09.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012109705"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.6789", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013901395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2008.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015143656", 
          "https://doi.org/10.1038/leu.2008.58"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa064320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018697395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1479-5876-5-42", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019767882", 
          "https://doi.org/10.1186/1479-5876-5-42"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/cgt.2011.63", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025767481", 
          "https://doi.org/10.1038/cgt.2011.63"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.047", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026768698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031051961", 
          "https://doi.org/10.1038/sj.onc.1208774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031051961", 
          "https://doi.org/10.1038/sj.onc.1208774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031051961", 
          "https://doi.org/10.1038/sj.onc.1208774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200103153441101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031768583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.7164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036621976"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djq310", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037022855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2011.138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040597290", 
          "https://doi.org/10.1038/bjc.2011.138"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2009.09.018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040904550"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/mol.108.047365", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045088072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1546", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046968716"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.24995", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047175416"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.24995", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047175416"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-0701", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048062146"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2007.00705.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050146971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205794", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050596563", 
          "https://doi.org/10.1038/sj.onc.1205794"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205794", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050596563", 
          "https://doi.org/10.1038/sj.onc.1205794"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2008-01-135319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050934133"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1677/erc.1.00671", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052544975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.06.171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075189858", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076607157", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.1.103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077944782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078440580", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-12", 
    "datePublishedReg": "2012-12-01", 
    "description": "BACKGROUND: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease. HER2-based vaccines induce polyclonal antibody responses against HER2 that demonstrate enhanced anti-tumor activity when combined with lapatinib in murine models. We wished to test the clinical safety, immunogenicity, and activity of a HER2-based cancer vaccine, when combined with lapatinib.\nMETHODS: We immunized women (n = 12) with metastatic, trastuzumab-refractory, HER2-overexpressing breast cancer with dHER2, a recombinant protein consisting of extracellular domain (ECD) and a portion of the intracellular domain (ICD) of HER2 combined with the adjuvant AS15, containing MPL, QS21, CpG and liposome. Lapatinib (1250 mg/day) was administered concurrently. Peripheral blood antibody and T cell responses were measured.\nRESULTS: This regimen was well tolerated, with no cardiotoxicity. Anti-HER2-specific antibody was induced in all patients whereas HER2-specific T cells were detected in one patient. Preliminary analyses of patient serum demonstrated downstream signaling inhibition in HER2 expressing tumor cells. The median time to progression was 55 days, with the majority of patients progressing prior to induction of peak anti-HER2 immune responses; however, 300-day overall survival was 92% (95% CI: 77-100%).\nCONCLUSIONS: dHER2 combined with lapatinib was safe and immunogenic with promising long term survival in those with HER2-overexpressing breast cancers refractory to trastuzumab. Further studies to define the anticancer activity of the antibodies induced by HER2 vaccines along with lapatinib are underway.\nTRIAL REGISTRY: ClinicalTrials.gov NCT00952692.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1479-5876-10-28", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.7135111", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1032886", 
        "issn": [
          "1479-5876"
        ], 
        "name": "Journal of Translational Medicine", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "name": "Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion", 
    "pagination": "28", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d72eac9771fa437d2103f43f0d7445f6d82ce572c4283c70df9dd92257264dc4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22325452"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101190741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1479-5876-10-28"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045174623"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1479-5876-10-28", 
      "https://app.dimensions.ai/details/publication/pub.1045174623"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T23:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000515.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1479-5876-10-28"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-10-28'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-10-28'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-10-28'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-10-28'


 

This table displays all metadata directly associated to this object as RDF triples.

331 TRIPLES      21 PREDICATES      78 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1479-5876-10-28 schema:about N032294b060734821b1b552fd8664b842
2 N0c1040db69af4408a2d94a9d7eede40d
3 N286ee8d5730e4815a79d98738f5d9f9e
4 N421f0b420ba74bc7b7416dcaa343805b
5 N496bcbd4cfad4a5f8e0a473264ba6251
6 N52ee5f2a03ef4cfd964f1e455aedba0c
7 N77f110d1162a4898b44f07a920ed686e
8 N7b0da1367a514b3f94fed2b8a97c0803
9 N9becc92522124cb4a223384b47dad16b
10 Na235360893294d14ba77c046330be9ee
11 Nb22a56a178f248f4b1867cf89b5bc71f
12 Nd73f83fe5ef646fea016ea7d41662a8a
13 Ne0bac835f24c40dc96d3ce4ea73a99cf
14 Neb416eea828f4028a3a3a0f7bda3fcbb
15 Nf109472eaaad48c7803f53b25ab2cdb7
16 Nfa5ba74c5a3b4378af62cc7209729c38
17 Nfff58d34c7224579a33d49e954caca88
18 anzsrc-for:11
19 anzsrc-for:1107
20 schema:author N836592fe68a640b3813931d223ae0686
21 schema:citation sg:pub.10.1007/s10637-010-9415-5
22 sg:pub.10.1038/bjc.2011.138
23 sg:pub.10.1038/cgt.2011.63
24 sg:pub.10.1038/leu.2008.58
25 sg:pub.10.1038/sj.onc.1205794
26 sg:pub.10.1038/sj.onc.1208774
27 sg:pub.10.1186/1479-5876-5-42
28 https://app.dimensions.ai/details/publication/pub.1075189858
29 https://app.dimensions.ai/details/publication/pub.1076607157
30 https://app.dimensions.ai/details/publication/pub.1078440580
31 https://doi.org/10.1002/ijc.24995
32 https://doi.org/10.1016/j.vaccine.2009.09.018
33 https://doi.org/10.1056/nejm200103153441101
34 https://doi.org/10.1056/nejmoa064320
35 https://doi.org/10.1093/annonc/mdn759
36 https://doi.org/10.1093/jnci/djq310
37 https://doi.org/10.1111/j.1349-7006.2007.00705.x
38 https://doi.org/10.1124/mol.108.047365
39 https://doi.org/10.1158/1078-0432.ccr-06-1546
40 https://doi.org/10.1158/1078-0432.ccr-07-0701
41 https://doi.org/10.1158/1078-0432.ccr-08-2484
42 https://doi.org/10.1158/1078-0432.ccr-09-2549
43 https://doi.org/10.1182/blood-2007-02-075945
44 https://doi.org/10.1182/blood-2008-01-135319
45 https://doi.org/10.1200/jco.1990.8.1.103
46 https://doi.org/10.1200/jco.2002.06.171
47 https://doi.org/10.1200/jco.2004.09.005
48 https://doi.org/10.1200/jco.2005.03.047
49 https://doi.org/10.1200/jco.2007.15.7164
50 https://doi.org/10.1200/jco.2008.20.6789
51 https://doi.org/10.1200/jco.2008.21.4437
52 https://doi.org/10.1677/erc.1.00671
53 schema:datePublished 2012-12
54 schema:datePublishedReg 2012-12-01
55 schema:description BACKGROUND: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease. HER2-based vaccines induce polyclonal antibody responses against HER2 that demonstrate enhanced anti-tumor activity when combined with lapatinib in murine models. We wished to test the clinical safety, immunogenicity, and activity of a HER2-based cancer vaccine, when combined with lapatinib. METHODS: We immunized women (n = 12) with metastatic, trastuzumab-refractory, HER2-overexpressing breast cancer with dHER2, a recombinant protein consisting of extracellular domain (ECD) and a portion of the intracellular domain (ICD) of HER2 combined with the adjuvant AS15, containing MPL, QS21, CpG and liposome. Lapatinib (1250 mg/day) was administered concurrently. Peripheral blood antibody and T cell responses were measured. RESULTS: This regimen was well tolerated, with no cardiotoxicity. Anti-HER2-specific antibody was induced in all patients whereas HER2-specific T cells were detected in one patient. Preliminary analyses of patient serum demonstrated downstream signaling inhibition in HER2 expressing tumor cells. The median time to progression was 55 days, with the majority of patients progressing prior to induction of peak anti-HER2 immune responses; however, 300-day overall survival was 92% (95% CI: 77-100%). CONCLUSIONS: dHER2 combined with lapatinib was safe and immunogenic with promising long term survival in those with HER2-overexpressing breast cancers refractory to trastuzumab. Further studies to define the anticancer activity of the antibodies induced by HER2 vaccines along with lapatinib are underway. TRIAL REGISTRY: ClinicalTrials.gov NCT00952692.
56 schema:genre research_article
57 schema:inLanguage en
58 schema:isAccessibleForFree true
59 schema:isPartOf Na3bab4b9e6c445c2b609edb82b477f47
60 Naffc304b119f45d291fdae18058b1037
61 sg:journal.1032886
62 schema:name Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
63 schema:pagination 28
64 schema:productId N13e84b8ef51441299b2fae2ed193cdf5
65 N84546a51a76b4f078ec8ba02a970b2fa
66 Nbf674011cd1e4a9b82e0667399cb4a38
67 Ncb9c3f72d11c4f2daf6bd662b607dcea
68 Nf67df03e5093480e86abd0c411b592c3
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045174623
70 https://doi.org/10.1186/1479-5876-10-28
71 schema:sdDatePublished 2019-04-10T23:25
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher N5b9b6a7b27e347268a6c6fa296106c9d
74 schema:url http://link.springer.com/10.1186%2F1479-5876-10-28
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N0156963f549b4b439c92a0e833323d4a rdf:first sg:person.014466504320.10
79 rdf:rest N950aea9876334eae842e8aae2c232537
80 N032294b060734821b1b552fd8664b842 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Female
82 rdf:type schema:DefinedTerm
83 N0c1040db69af4408a2d94a9d7eede40d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Vaccination
85 rdf:type schema:DefinedTerm
86 N13e84b8ef51441299b2fae2ed193cdf5 schema:name pubmed_id
87 schema:value 22325452
88 rdf:type schema:PropertyValue
89 N2196a2e304e6417ba1c1a7a9acf87bb3 rdf:first sg:person.01032053762.30
90 rdf:rest N0156963f549b4b439c92a0e833323d4a
91 N286ee8d5730e4815a79d98738f5d9f9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Demography
93 rdf:type schema:DefinedTerm
94 N421f0b420ba74bc7b7416dcaa343805b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Aged
96 rdf:type schema:DefinedTerm
97 N496bcbd4cfad4a5f8e0a473264ba6251 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Quinazolines
99 rdf:type schema:DefinedTerm
100 N4a011f7169ee4189a24909ede83a62dd rdf:first sg:person.01245021610.91
101 rdf:rest N67801c4ac3134de2a27d3d85c50f9d1a
102 N52ee5f2a03ef4cfd964f1e455aedba0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Humans
104 rdf:type schema:DefinedTerm
105 N5b9b6a7b27e347268a6c6fa296106c9d schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 N67801c4ac3134de2a27d3d85c50f9d1a rdf:first sg:person.01242656120.60
108 rdf:rest Ncae0619ea3654d64a7e3ec0d35b7bd5a
109 N699a5a487be545a1aa044ef620b82fc0 rdf:first sg:person.07741424047.51
110 rdf:rest Nc0483ac13a7a48a48c9fd12bfb2dbf7d
111 N6ae7b5cca15c447e9d58c7471aa45de0 rdf:first sg:person.01264356120.90
112 rdf:rest N699a5a487be545a1aa044ef620b82fc0
113 N77f110d1162a4898b44f07a920ed686e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Middle Aged
115 rdf:type schema:DefinedTerm
116 N7b0da1367a514b3f94fed2b8a97c0803 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Phosphorylation
118 rdf:type schema:DefinedTerm
119 N81e1b039642047a19c901f0a02fd8555 rdf:first sg:person.0610532363.22
120 rdf:rest N2196a2e304e6417ba1c1a7a9acf87bb3
121 N836592fe68a640b3813931d223ae0686 rdf:first sg:person.01315576133.11
122 rdf:rest N6ae7b5cca15c447e9d58c7471aa45de0
123 N84546a51a76b4f078ec8ba02a970b2fa schema:name doi
124 schema:value 10.1186/1479-5876-10-28
125 rdf:type schema:PropertyValue
126 N950aea9876334eae842e8aae2c232537 rdf:first sg:person.01137075433.49
127 rdf:rest N4a011f7169ee4189a24909ede83a62dd
128 N9becc92522124cb4a223384b47dad16b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Treatment Outcome
130 rdf:type schema:DefinedTerm
131 Na235360893294d14ba77c046330be9ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Antibody Formation
133 rdf:type schema:DefinedTerm
134 Na3bab4b9e6c445c2b609edb82b477f47 schema:volumeNumber 10
135 rdf:type schema:PublicationVolume
136 Naffc304b119f45d291fdae18058b1037 schema:issueNumber 1
137 rdf:type schema:PublicationIssue
138 Nb22a56a178f248f4b1867cf89b5bc71f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Immunotherapy
140 rdf:type schema:DefinedTerm
141 Nbf674011cd1e4a9b82e0667399cb4a38 schema:name readcube_id
142 schema:value d72eac9771fa437d2103f43f0d7445f6d82ce572c4283c70df9dd92257264dc4
143 rdf:type schema:PropertyValue
144 Nc0483ac13a7a48a48c9fd12bfb2dbf7d rdf:first sg:person.0706420433.90
145 rdf:rest N81e1b039642047a19c901f0a02fd8555
146 Ncae0619ea3654d64a7e3ec0d35b7bd5a rdf:first sg:person.01037147437.60
147 rdf:rest Ne7623accfb1240b388f7399fa19034b5
148 Ncb9c3f72d11c4f2daf6bd662b607dcea schema:name dimensions_id
149 schema:value pub.1045174623
150 rdf:type schema:PropertyValue
151 Nd73f83fe5ef646fea016ea7d41662a8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Protein Structure, Tertiary
153 rdf:type schema:DefinedTerm
154 Ndfd5238fe4964dc6a9d4430661391b67 rdf:first sg:person.012507420117.48
155 rdf:rest rdf:nil
156 Ne0bac835f24c40dc96d3ce4ea73a99cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Receptor, ErbB-2
158 rdf:type schema:DefinedTerm
159 Ne7623accfb1240b388f7399fa19034b5 rdf:first sg:person.01114717615.49
160 rdf:rest Ndfd5238fe4964dc6a9d4430661391b67
161 Neb416eea828f4028a3a3a0f7bda3fcbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Kaplan-Meier Estimate
163 rdf:type schema:DefinedTerm
164 Nf109472eaaad48c7803f53b25ab2cdb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Proto-Oncogene Proteins c-akt
166 rdf:type schema:DefinedTerm
167 Nf67df03e5093480e86abd0c411b592c3 schema:name nlm_unique_id
168 schema:value 101190741
169 rdf:type schema:PropertyValue
170 Nfa5ba74c5a3b4378af62cc7209729c38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Epitopes
172 rdf:type schema:DefinedTerm
173 Nfff58d34c7224579a33d49e954caca88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name T-Lymphocytes
175 rdf:type schema:DefinedTerm
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
180 schema:name Immunology
181 rdf:type schema:DefinedTerm
182 sg:grant.7135111 http://pending.schema.org/fundedItem sg:pub.10.1186/1479-5876-10-28
183 rdf:type schema:MonetaryGrant
184 sg:journal.1032886 schema:issn 1479-5876
185 schema:name Journal of Translational Medicine
186 rdf:type schema:Periodical
187 sg:person.01032053762.30 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
188 schema:familyName Ren
189 schema:givenName Xiu-Rong
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032053762.30
191 rdf:type schema:Person
192 sg:person.01037147437.60 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
193 schema:familyName Wei
194 schema:givenName Junping
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037147437.60
196 rdf:type schema:Person
197 sg:person.01114717615.49 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
198 schema:familyName Osada
199 schema:givenName Takuya
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114717615.49
201 rdf:type schema:Person
202 sg:person.01137075433.49 schema:affiliation https://www.grid.ac/institutes/grid.425090.a
203 schema:familyName Castro
204 schema:givenName Henry
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137075433.49
206 rdf:type schema:Person
207 sg:person.01242656120.60 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
208 schema:familyName Spector
209 schema:givenName Neil
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242656120.60
211 rdf:type schema:Person
212 sg:person.01245021610.91 schema:affiliation https://www.grid.ac/institutes/grid.425090.a
213 schema:familyName Lehmann
214 schema:givenName Frederic
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245021610.91
216 rdf:type schema:Person
217 sg:person.012507420117.48 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
218 schema:familyName Lyerly
219 schema:givenName H Kim
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012507420117.48
221 rdf:type schema:Person
222 sg:person.01264356120.90 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
223 schema:familyName Blackwell
224 schema:givenName Kimberly
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264356120.90
226 rdf:type schema:Person
227 sg:person.01315576133.11 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
228 schema:familyName Hamilton
229 schema:givenName Erika
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315576133.11
231 rdf:type schema:Person
232 sg:person.014466504320.10 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
233 schema:familyName Chen
234 schema:givenName Wei
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014466504320.10
236 rdf:type schema:Person
237 sg:person.0610532363.22 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
238 schema:familyName Broadwater
239 schema:givenName Gloria
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610532363.22
241 rdf:type schema:Person
242 sg:person.0706420433.90 schema:affiliation https://www.grid.ac/institutes/grid.425090.a
243 schema:familyName Clay
244 schema:givenName Timothy M
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706420433.90
246 rdf:type schema:Person
247 sg:person.07741424047.51 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
248 schema:familyName Hobeika
249 schema:givenName Amy C
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07741424047.51
251 rdf:type schema:Person
252 sg:pub.10.1007/s10637-010-9415-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006267870
253 https://doi.org/10.1007/s10637-010-9415-5
254 rdf:type schema:CreativeWork
255 sg:pub.10.1038/bjc.2011.138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040597290
256 https://doi.org/10.1038/bjc.2011.138
257 rdf:type schema:CreativeWork
258 sg:pub.10.1038/cgt.2011.63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025767481
259 https://doi.org/10.1038/cgt.2011.63
260 rdf:type schema:CreativeWork
261 sg:pub.10.1038/leu.2008.58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015143656
262 https://doi.org/10.1038/leu.2008.58
263 rdf:type schema:CreativeWork
264 sg:pub.10.1038/sj.onc.1205794 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050596563
265 https://doi.org/10.1038/sj.onc.1205794
266 rdf:type schema:CreativeWork
267 sg:pub.10.1038/sj.onc.1208774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031051961
268 https://doi.org/10.1038/sj.onc.1208774
269 rdf:type schema:CreativeWork
270 sg:pub.10.1186/1479-5876-5-42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019767882
271 https://doi.org/10.1186/1479-5876-5-42
272 rdf:type schema:CreativeWork
273 https://app.dimensions.ai/details/publication/pub.1075189858 schema:CreativeWork
274 https://app.dimensions.ai/details/publication/pub.1076607157 schema:CreativeWork
275 https://app.dimensions.ai/details/publication/pub.1078440580 schema:CreativeWork
276 https://doi.org/10.1002/ijc.24995 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047175416
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1016/j.vaccine.2009.09.018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040904550
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1056/nejm200103153441101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031768583
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1056/nejmoa064320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018697395
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1093/annonc/mdn759 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011354734
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1093/jnci/djq310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037022855
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1111/j.1349-7006.2007.00705.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1050146971
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1124/mol.108.047365 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045088072
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1158/1078-0432.ccr-06-1546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046968716
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1158/1078-0432.ccr-07-0701 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048062146
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1158/1078-0432.ccr-08-2484 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009361534
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1158/1078-0432.ccr-09-2549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000633777
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1182/blood-2007-02-075945 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006579746
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1182/blood-2008-01-135319 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050934133
303 rdf:type schema:CreativeWork
304 https://doi.org/10.1200/jco.1990.8.1.103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077944782
305 rdf:type schema:CreativeWork
306 https://doi.org/10.1200/jco.2002.06.171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203009
307 rdf:type schema:CreativeWork
308 https://doi.org/10.1200/jco.2004.09.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012109705
309 rdf:type schema:CreativeWork
310 https://doi.org/10.1200/jco.2005.03.047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026768698
311 rdf:type schema:CreativeWork
312 https://doi.org/10.1200/jco.2007.15.7164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036621976
313 rdf:type schema:CreativeWork
314 https://doi.org/10.1200/jco.2008.20.6789 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013901395
315 rdf:type schema:CreativeWork
316 https://doi.org/10.1200/jco.2008.21.4437 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001671107
317 rdf:type schema:CreativeWork
318 https://doi.org/10.1677/erc.1.00671 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052544975
319 rdf:type schema:CreativeWork
320 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
321 schema:name Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
322 Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA
323 Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA
324 Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, NC, USA
325 rdf:type schema:Organization
326 https://www.grid.ac/institutes/grid.26009.3d schema:alternateName Duke University
327 schema:name Cancer Statistical Center, Duke Cancer Institute, Durham, NC, USA
328 rdf:type schema:Organization
329 https://www.grid.ac/institutes/grid.425090.a schema:alternateName GlaxoSmithKline (Belgium)
330 schema:name GlaxoSmithKline Biologicals, Rixensart, Belgium
331 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...